Serum protein responses to Dietary Approaches to Stop Hypertension (DASH) and DASH-Sodium trials and associations with blood pressure changes.
Journal
Journal of hypertension
ISSN: 1473-5598
Titre abrégé: J Hypertens
Pays: Netherlands
ID NLM: 8306882
Informations de publication
Date de publication:
01 Oct 2024
01 Oct 2024
Historique:
medline:
29
8
2024
pubmed:
29
8
2024
entrez:
28
8
2024
Statut:
ppublish
Résumé
The Dietary Approaches to Stop Hypertension (DASH) diet reduces blood pressure, but the mechanisms underlying DASH diet-blood pressure relations are not well understood. Proteomic measures may provide insights into the pathophysiological mechanisms through which the DASH diet reduces blood pressure. The DASH (1994-1996) and DASH-Sodium (1997-1999) trials were multicenter, randomized-controlled feeding trials. Proteomic profiling was conducted in serum collected at the end of the feeding period (DASH, N = 215; DASH-Sodium, N = 390). Multivariable linear regression models were used to identify interactions between 71 DASH diet-related proteins and changes in systolic and diastolic blood pressure. Estimates were meta-analyzed across both trials. Elastic net models were used to identify proteins that predict changes in blood pressure. Ten significant interactions were identified [systolic blood pressure: seven proteins; diastolic blood pressure: three proteins], which represented nine unique proteins. A high level of renin at the end of the feeding period was associated with greater reductions in diastolic blood pressure in individuals consuming the control than DASH diets. A high level of procollagen c-endopeptidase enhancer 1 (PCOLCE) and collagen triple helix repeat-containing protein 1 (CTHRC1) were associated with greater reductions in systolic blood pressure in individuals consuming the DASH than control diets, and with elevations in systolic blood pressure in individuals consuming the control diets (P for interaction for all tests < 0.05). Elastic net models identified six additional proteins that predicted change in blood pressure. Several novel proteins were identified that may provide some insight into the relationship between the DASH diet and blood pressure.
Identifiants
pubmed: 39196693
doi: 10.1097/HJH.0000000000003828
pii: 00004872-202410000-00021
doi:
Substances chimiques
Blood Proteins
0
Banques de données
ClinicalTrials.gov
['NCT03403166']
Types de publication
Journal Article
Randomized Controlled Trial
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
1823-1830Informations de copyright
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
Références
Appel LJ, Moore TJ, Obarzanek E, Vollmer WM, Svetkey LP, Sacks FM, et al. A clinical trial of the effects of dietary patterns on blood pressure. N Engl J Med 1997; 336:1117–1124.
Sacks FM, Svetkey LP, Vollmer WM, Appel LJ, Bray GA, Harsha D, et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. N Engl J Med 2001; 344:3–10.
Fung TT, Chiuve SE, McCullough ML, Rexrode KM, Logroscino G, Hu FB. Adherence to a DASH-style diet and risk of coronary heart disease and stroke in women. Arch Intern Med 2008; 168:713–720.
Schwingshackl L, Chaimani A, Schwedhelm C, Toledo E, Pünsch M, Hoffmann G, et al. Comparative effects of different dietary approaches on blood pressure in hypertensive and prehypertensive patients: a systematic review and network meta-analysis. Crit Rev Food Sci Nutr 2019; 59:2674–2687.
Maris SA, Williams JS, Sun B, Brown S, Mitchell GF, Conlin PR. Interactions of the DASH diet with the renin-angiotensin-aldosterone system. Curr Dev Nutr 2019; 3:nzz091.
Chen Q, Turban S, Miller ER, Appel LJ. The effects of dietary patterns on plasma renin activity: results from the Dietary Approaches to Stop Hypertension trial. J Hum Hypertens 2012; 26:664–669.
Akita S, Sacks FM, Svetkey LP, Conlin PR, Kimura G. DASH-Sodium Trial Collaborative Research Group. Effects of the Dietary Approaches to Stop Hypertension (DASH) diet on the pressure-natriuresis relationship. Hypertension 2003; 42:8–13.
Lin P-H, Allen JD, Li Y-J, Yu M, Lien LF, Svetkey LP. Blood pressure-lowering mechanisms of the DASH dietary pattern. J Nutr Metab 2012; 2012:472396.
Kim H, Lichtenstein AH, Ganz P, Du S, Tang O, Yu B, et al. Identification of protein biomarkers of the Dietary Approaches to Stop Hypertension Diet in randomized feeding studies and validation in an observational study. J Am Heart Assoc 2023; 12:e028821.
Sacks FM, Obarzanek E, Windhauser MM, Svetkey LP, Vollmer WM, McCullough M, et al. Rationale and design of the Dietary Approaches to Stop Hypertension trial (DASH). A multicenter controlled-feeding study of dietary patterns to lower blood pressure. Ann Epidemiol 1995; 5:108–118.
Svetkey LP, Sacks FM, Obarzanek E, Vollmer WM, Appel LJ, Lin PH, et al. The DASH diet, sodium Intake and blood pressure trial (DASH-sodium): rationale and design. DASH-Sodium Collaborative Research Group. J Am Diet Assoc 1999; 99:S96–S104.
Giffen CA, Carroll LE, Adams JT, Brennan SP, Coady SA, Wagner EL. Providing contemporary access to historical biospecimen collections: development of the NHLBI Biologic Specimen and Data Repository Information Coordinating Center (BioLINCC). Biopreserv Biobank 2015; 13:271–279.
Williams SA, Kivimaki M, Langenberg C, Hingorani AD, Casas JP, Bouchard C, et al. Plasma protein patterns as comprehensive indicators of health. Nat Med 2019; 25:1851–1857.
Gold L, Ayers D, Bertino J, Bock C, Bock A, Brody EN, et al. Aptamer-based multiplexed proteomic technology for biomarker discovery. PLoS One 2010; 5:e15004.
Candia J, Cheung F, Kotliarov Y, Fantoni G, Sellers B, Griesman T, et al. Assessment of variability in the SOMAscan assay. Sci Rep 2017; 7:14248.
Fountain JH, Kaur J, Lappin SL. Physiology, renin angiotensin system. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2023. Available at: http://www.ncbi.nlm.nih.gov/books/NBK470410/ [Accessed 29 May2023].
Hall JE. The renin-angiotensin system: renal actions and blood pressure regulation. Compr Ther 1991; 17:8–17.
Conlin PR, Erlinger TP, Bohannon A, Miller ER, Appel LJ, Svetkey LP, et al. The DASH diet enhances the blood pressure response to losartan in hypertensive patients. Am J Hypertens 2003; 16:337–342.
Shalitin N, Schlesinger H, Levy MJ, Kessler E, Kessler-Icekson G. Expression of procollagen C-proteinase enhancer in cultured rat heart fibroblasts: evidence for co-regulation with type I collagen. J Cell Biochem 2003; 90:397–407.
Lagoutte P, Bettler E, Vadon-Le Goff S, Moali C. Procollagen C-proteinase enhancer-1 (PCPE-1), a potential biomarker and therapeutic target for fibrosis. Matrix Biol Plus 2021; 11:100062.
Pyagay P, Heroult M, Wang Q, Lehnert W, Belden J, Liaw L, et al. Collagen triple helix repeat containing 1, a novel secreted protein in injured and diseased arteries, inhibits collagen expression and promotes cell migration. Circ Res 2005; 96:261–268.
Peterkofsky B. Ascorbate requirement for hydroxylation and secretion of procollagen: relationship to inhibition of collagen synthesis in scurvy. Am J Clin Nutr 1991; 54:1135S–1140S.
LeClair RJ, Durmus T, Wang Q, Pyagay P, Terzic A, Lindner V. Cthrc1 is a novel inhibitor of transforming growth factor-beta signaling and neointimal lesion formation. Circ Res 2007; 100:826–833.
Kanaki T, Morisaki N, Bujo H, Takahashi K, Ishii I, Saito Y. The regulatory expression of procollagen COOH-terminal proteinase enhancer in the proliferation of vascular smooth muscle cells. Biochem Biophys Res Commun 2000; 270:1049–1054.
Lijnen PJ, Petrov VV, Fagard RH. Association between transforming growth factor-beta and hypertension. Am J Hypertens 2003; 16:604–611.
O’Callaghan CJ, Williams B. Mechanical strain-induced extracellular matrix production by human vascular smooth muscle cells: role of TGF-beta(1). Hypertension 2000; 36:319–324.
Yndestad A, Ueland T, Øie E, Florholmen G, Halvorsen B, Attramadal H, et al. Elevated levels of activin A in heart failure: potential role in myocardial remodeling. Circulation 2004; 109:1379–1385.
Tsai Y-L, Chang C-C, Liu L-K, Huang P-H, Chen L-K, Lin S-J. The association between serum activin A levels and hypertension in the elderly: a cross-sectional analysis from I-Lan Longitudinal Aging Study. Am J Hypertens 2018; 31:369–374.
Gallo G, Volpe M, Savoia C. Endothelial dysfunction in hypertension: current concepts and clinical implications. Front Med (Lausanne) 2022; 8:798958.
Kronenberg F, Kollerits B, Kiechl S, Lamina C, Kedenko L, Meisinger C, et al. Plasma concentrations of afamin are associated with the prevalence and development of metabolic syndrome. Circ Cardiovasc Genet 2014; 7:822–829.
Kollerits B, Lamina C, Huth C, Marques-Vidal P, Kiechl S, Seppälä I, et al. Plasma concentrations of afamin are associated with prevalent and incident type 2 diabetes: a pooled analysis in more than 20,000 individuals. Diabetes Care 2017; 40:1386–1393.
Köninger A, Enekwe A, Mach P, Andrikos D, Schmidt B, Frank M, et al. Afamin: an early predictor of preeclampsia. Arch Gynecol Obstet 2018; 298:1009–1016.
Vogt L, Schmitz N, Kurrer MO, Bauer M, Hinton HI, Behnke S, et al. VSIG4, a B7 family-related protein, is a negative regulator of T cell activation. J Clin Invest 2006; 116:2817–2826.
Li J, Diao B, Guo S, Huang X, Yang C, Feng Z, et al. VSIG4 inhibits proinflammatory macrophage activation by reprogramming mitochondrial pyruvate metabolism. Nat Commun 2017; 8:1322.
Martìn-Padura I, Lostaglio S, Schneemann M, Williams L, Romano M, Fruscella P, et al. Junctional adhesion molecule, a novel member of the immunoglobulin superfamily that distributes at intercellular junctions and modulates monocyte transmigration. J Cell Biol 1998; 142:117–127.
Mandell KJ, Parkos CA. The JAM family of proteins. Adv Drug Deliv Rev 2005; 57:857–867.
Babinska A, Azari BM, Salifu MO, Liu R, Jiang X-C, Sobocka MB, et al. The F11 receptor (F11R/JAM-A) in atherothrombosis: overexpression of F11R in atherosclerotic plaques. Thromb Haemost 2007; 97:272–281.
Cavusoglu E, Kornecki E, Sobocka MB, Babinska A, Ehrlich YH, Chopra V, et al. Association of plasma levels of F11 receptor/junctional adhesion molecule-A (F11R/JAM-A) with human atherosclerosis. J Am Coll Cardiol 2007; 50:1768–1776.
Ong KL, Leung RYH, Babinska A, Salifu MO, Ehrlich YH, Kornecki E, et al. Elevated plasma level of soluble F11 receptor/junctional adhesion molecule-A (F11R/JAM-A) in hypertension. Am J Hypertens 2009; 22:500–505.
Adedayo A, Eluwole A, Tedla F, Kremer A, Khan M, Mastrogiovanni N, et al. Relationship between the soluble F11 receptor and annexin A5 in African Americans patients with type-2 diabetes mellitus. Biomedicines 2022; 10:1818.
Sakamoto T, Mori K, Nakahara K, Miyazato M, Kangawa K, Sameshima H, et al. Neuromedin S exerts an antidiuretic action in rats. Biochem Biophys Res Commun 2007; 361:457–461.
Pathak GP, Shah R, Kennedy BE, Murphy JP, Clements D, Konda P, et al. RTN4 knockdown dysregulates the AKT pathway, destabilizes the cytoskeleton, and enhances paclitaxel-Induced cytotoxicity in cancers. Mol Ther 2018; 26:2019–2033.
Cantalupo A, Zhang Y, Kothiya M, Galvani S, Obinata H, Bucci M, et al. Nogo-B regulates endothelial sphingolipid homeostasis to control vascular function and blood pressure. Nat Med 2015; 21:1028–1037.
Bellia F, Vecchio G, Rizzarelli E. Carnosinases, their substrates and diseases. Molecules 2014; 19:2299–2329.
Ghodsi R, Kheirouri S. Carnosine and advanced glycation end products: a systematic review. Amino Acids 2018; 50:1177–1186.
Qiu J, Yard BA, Krämer BK, van Goor H, van Dijk P, Kannt A. Association between serum carnosinase concentration and activity and renal function impairment in a type-2 diabetes cohort. Front Pharmacol 2022; 13:899057.
Zhou Z, Liu X, Zhang S, Qi X, Zhang Q, Yard B, et al. Correlation between serum carnosinase concentration and renal damage in diabetic nephropathy patients. Amino Acids 2021; 53:687–700.
Altieri B, Sbiera S, Casa SD, Weigand I, Wild V, Steinhauer S, et al. Livin/BIRC7 expression as malignancy marker in adrenocortical tumors. Oncotarget 2016; 8:9323–9338.
Erl W, Hansson GK, de Martin R, Draude G, Weber KS, Weber C. Nuclear factor-kappa B regulates induction of apoptosis and inhibitor of apoptosis protein-1 expression in vascular smooth muscle cells. Circ Res 1999; 84:668–677.
Sattar Z, Lora A, Jundi B, Railwah C, Geraghty P. The S100 protein family as players and therapeutic targets in pulmonary diseases. Pulm Med 2021; 2021:5488591.
Heizmann CW. S100 proteins: diagnostic and prognostic biomarkers in laboratory medicine. Biochim Biophys Acta Mol Cell Res 2019; 1866:1197–1206.
Katono K, Sato Y, Kobayashi M, Saito K, Nagashio R, Ryuge S, et al. Clinicopathological significance of S100A14 expression in lung adenocarcinoma. Oncol Res Treat 2017; 40:594–602.
Hintsch G, Zurlinden A, Meskenaite V, Steuble M, Fink-Widmer K, Kinter J, et al. The calsyntenins – a family of postsynaptic membrane proteins with distinct neuronal expression patterns. Mol Cell Neurosci 2002; 21:393–409.